Topical Pimecrolimus 1% Cream for Resistant Seborrheic Dermatitis of the Face

[1]  D. Cicek,et al.  Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: A randomized clinical study , 2009, The Journal of dermatological treatment.

[2]  M. Weichenthal,et al.  Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. , 2009, The Journal of allergy and clinical immunology.

[3]  F. Eskioğlu,et al.  Experience with repetitive use of pimecrolimus: exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis. , 2009, Journal of dermatological treatment (Print).

[4]  M. Boguniewicz,et al.  Sustained Efficacy and Safety of Pimecrolimus Cream 1% when Used Long‐term (up to 26 Weeks) to Treat Children with Atopic Dermatitis , 2008, Pediatric dermatology.

[5]  E. Warshaw,et al.  Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. , 2007, Journal of the American Academy of Dermatology.

[6]  A. Firooz,et al.  Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. , 2006, Archives of dermatology.

[7]  P. R. Cunha.  Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. , 2006, Acta dermato-venereologica.

[8]  A. Katsambas,et al.  Pimecrolimus cream 1% vs. betamethasone 17‐valerate 0·1% cream in the treatment of seborrhoeic dermatitis. A randomized open‐label clinical trial , 2004, The British journal of dermatology.

[9]  E. Rallis,et al.  Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. , 2004, Drugs under experimental and clinical research.

[10]  Aditya K. Gupta,et al.  Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. , 2003, Clinics in dermatology.

[11]  J. Chung,et al.  Pimecrolimus does not affect the differentiation, maturation and function of human monocyte‐derived dendritic cells, in contrast to corticosteroids , 2003, Clinical and experimental immunology.

[12]  L. T. Quan,et al.  Topical pimecrolimus in the treatment of seborrheic dermatitis. , 2003, Dermatology online journal.

[13]  A. Qureishi,et al.  Correlation of the density of yeast Malassezia with the clinical severity of seborrhoeic dermatitis. , 2002, JPMA. The Journal of the Pakistan Medical Association.

[14]  M. Meurer,et al.  Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study , 2002, Dermatology.

[15]  A. Winiski,et al.  A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology , 1999, The British journal of dermatology.

[16]  Bräutigam,et al.  The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion , 1998, The British journal of dermatology.

[17]  H. Schuurman,et al.  A novel anti‐inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology , 1997, The British journal of dermatology.

[18]  D. Kelly,et al.  Seborrheic dermatitis. , 1950, The Journal of the Indiana State Medical Association.